Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Weekly Digest – 14 November to 20 November 2026

Approval  ·  Weekly Digest - 14 November to 20 November 2026
Imfinzi approved in the US in novel regimen with neoadjuvant Enfortumab vedotin for patients with muscle-invasive bladder cancer

Weekly Digest – November 2026 Weekly Digest – November 2026 13 November 2026: Imfinzi approved in the US in novel regimen with neoadjuvant Enfortumab vedotin for patients with muscle-invasive bladder cancer  AstraZeneca received US FDA approval on 13 November 2026 for […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 14 November to 20 November 2026
Sonesitatug vedotin granted priority review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

Weekly Digest – November 2026 Weekly Digest – November 2026 19 November 2026: Sonesitatug vedotin granted priority review in the US for 2nd and later-line treatment of patients with CLDN18.2+ advanced gastric/GEJ cancers AstraZeneca’s biologics license application  for sonesitatug vedotin  has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 14 November to 20 November 2026
Innovent Biologics announced that Takeda has received SAKIGAKE designation from the MHLW for its tanconazole atotatamumab

Weekly Digest – November 2026 Weekly Digest – November 2026 20 November 2026: Innovent Biologics announced that Takeda has received SAKIGAKE  designation from the MHLW for its TAK-921 Takeda Pharmaceutical received SAKIGAKE designation from MHLW for TAK-921 for CLDN18.2-positive, unresectable, advanced […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 14 November to 20 November 2026
IDEAYA reports FDA alignment on IDE849 phase 2/3 registrational trial designs in neuroendocrine carcinomas

Weekly Digest – November 2026 Weekly Digest – November 2026 16 November 2026: IDEAYA reports FDA alignment on IDE849 phase 2/3 registrational trial designs in neuroendocrine carcinomas  IDEAYA Biosciences announced successful US FDA type C meeting discussions on the registrational development […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 14 November to 20 November 2026
OBI Pharma signs collaboration and license agreement with Novartis

Weekly Digest – November 2026 Weekly Digest – November 2026 16 November 2026: OBI Pharma signs collaboration and license agreement with Novartis  OBI Pharma entered into a collaboration and license agreement with Novartis Pharma AG to develop next-generation ADC using OBI’s […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 14 November to 20 November 2026
mAbxience and OncoPrecision announce manufacturing and investment agreement for ONC001

Weekly Digest – November 2026 Weekly Digest – November 2026 18 November 2026: mAbxience and OncoPrecision announce manufacturing and investment agreement for ONC001 mAbxience, a wholly owned subsidiary of Fresenius, entered into an investment, development and manufacturing agreement with OncoPrecision for ONC001, […]

by Sandhya Ramalingam

Continue Reading


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id